Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Assets: 2017-2025

Historic Assets for Dianthus Therapeutics (DNTH) over the last 7 years, with Sep 2025 value amounting to $577.4 million.

  • Dianthus Therapeutics' Assets rose 63.01% to $577.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $577.4 million, marking a year-over-year increase of 63.01%. This contributed to the annual value of $374.0 million for FY2024, which is 108.47% up from last year.
  • Dianthus Therapeutics' Assets amounted to $577.4 million in Q3 2025, which was up 77.09% from $326.1 million recorded in Q2 2025.
  • In the past 5 years, Dianthus Therapeutics' Assets ranged from a high of $577.4 million in Q3 2025 and a low of $78.6 million during Q2 2023.
  • Its 3-year average for Assets is $296.9 million, with a median of $348.6 million in 2025.
  • In the last 5 years, Dianthus Therapeutics' Assets plummeted by 57.07% in 2023 and then soared by 369.19% in 2024.
  • Over the past 4 years, Dianthus Therapeutics' Assets (Quarterly) stood at $83.1 million in 2022, then skyrocketed by 115.86% to $179.4 million in 2023, then soared by 108.47% to $374.0 million in 2024, then spiked by 63.01% to $577.4 million in 2025.
  • Its Assets was $577.4 million in Q3 2025, compared to $326.1 million in Q2 2025 and $348.6 million in Q1 2025.